Skip to content6
60 Degrees Pharmaceuticals, Inc.
6
SXTPW60 Degrees Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue$100.93K$100.93K−19.2% vs Q2 2024 Net Income-$1.73M-$1.73MN/M vs Q2 2024 EPS Diluted-$5.01-$5.01N/M vs Q2 2024 Gross Profit$50,881+43.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
60 Degrees Pharmaceuticals, Inc. · CIK 1946563 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,450,128N/M Free Cash Flowderived-$1,497,451— Margins · derivedGross margin50.4%+22.1 pt vs Q2 2024
Operating margin-1591.5%+1760.3 pt vs Q2 2024
Net margin-1717.7%+1621.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 13, 2025 · 44 d after period end